Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy

Abstract

Background

Pegylated interferon (PEG-IFN)-α-2a improves the hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients. However, baseline factors predicting favourable responses to PEG-IFN-α-2a remain largely unknown.

Methods

A total of 115 HBeAg-positive chronic hepatitis B patients who had a pre-therapy serum alanine amino-transferase (ALT) level over two times the upper limit of normal and received PEG-IFN-α-2a for 6–12 months were consecutively enrolled according to the local reimbursed guidelines. HBeAg seroconversion and combined response defined as HBeAg seroconversion, HBV-DNA level <20,000 IU/ml as well as ALT normalization at 6 months off therapy were primary and secondary therapeutic end points, respectively. Baseline viral factors, including viral load, genotype and major sequences of precore stop codon/ basal core promoter (BCP), and host factors, including three single nucleotide polymorphisms among the HLA-DPA1, HLA-DPB1 and IL28B regions, were determined to correlate with therapeutic end points.

Results

HBeAg seroconversion and combined response rates were 26.1% and 18.3%, respectively. By multivariate analysis, BCP mutation (OR 8.04, 95% CI 2.00-32.28) and rs3077 G/G genotype (OR 3.49, 95% CI 1.12-10.84) were associated with a higher HBeAg seroconversion rate; BCP mutation (OR 9.28, 95% CI 1.92-44.99) and baseline viral load <2x10⁶ IU/ml (OR 4.78, 95% CI 1.37-16.69) were associated with a higher combined response rate.

Conclusions

BCP mutation is associated with higher HBeAg seroconversion and combined response rates at 6 months off therapy in HBeAg-positive chronic hepatitis B patients treated with PEG-IFN-α-2a. Genetic variants in the HLA-DPA1 region may also affect treatment-induced HBeAg seroconversion.

References

Kao

J.H.

, Chen

D.S.

Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395–403.

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

Iloeje

U.H.

, Yang

H.I.

, Su

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.

Liaw

Y.F.

, Sung

J.J.

, Chow

W.C.

Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.

Liaw

Y.F.

, Lau

G.K.

, Kao

J.H.

Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55: 2727–2734.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.

Buster

E.H.

, Hansen

B.E.

, Lau

G.K.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002–2009.

Tseng

T.C.

, Liu

C.J.

, Wang

C.C.

Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009; 14: 203–210.

Tseng

T.C.

, Liu

C.J.

, Wang

C.C.

A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008; 28: 1034–1041.

10.

Chotiyaputta

, Lok

A.S.

Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009; 6: 453–462.

11.

Erhardt

, Reineke

, Blondin

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716–725.

12.

Tangkijvanich

, Komolmit

, Mahachai

Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117–123.

13.

, Fellay

, Thompson

A.J.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

14.

Tanaka

, Nishida

, Sugiyama

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.

15.

Rauch

, Kutalik

, Descombes

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338–1345.

16.

Kamatani

, Wattanapokayakit

, Ochi

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591–595.

17.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–283.

18.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

19.

Yeh

S.H.

, Tsai

C.Y.

, Kao

J.H.

Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41: 659–666.

20.

Liu

C.J.

, Chen

P.J.

, Lai

M.Y.

A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003; 124: 80–90.

21.

Wigginton

J.E.

, Cutler

D.J.

, Abecasis

G.R.

A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 2005; 76: 887–893.

22.

Barrett

J.C.

, Fry

, Maller

Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

23.

Dudbridge

Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66: 87–98.

24.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

25.

Kurosaki

, Enomoto

, Asahina

Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996; 49: 115–123.

26.

Okamoto

, Tsuda

, Akahane

Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102–8110.

27.

Buckwold

V.E.

, Xu

, Yen

T.S.

Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J Gen Virol 1997; 78: 2055–2065.

28.

Günther

, Piwon

, Will

Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)→T, A(1762)→T and G(1764)→A mutations in the core promoter. J Gen Virol 1998; 79: 375–380.

29.

Baptista

, Kramvis

, Kew

M.C.

High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29: 946–953.

30.

Moriyama

Reduced antigen production by hepatitis B virus harbouring nucleotide deletions in the overlapping X gene and precore-core promoter. J Gen Virol 1997; 78: 1479–1486.

31.

Kao

J.H.

, Wu

N.H.

, Chen

P.J.

Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998–1002.

32.

Lin

C.L.

, Kao

J.H.

To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B. Clin Infect Dis 2007; 44: 1665–1666.

33.

King

J.K.

, Yeh

S.H.

, Lin

M.W.

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002; 36: 1416–1424.

34.

Chen

P.J.

, Lin

C.G.

, Lin

F.Y.

Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients. J Hum Genet 2006; 51: 984–991.

35.

Robek

M.D.

, Boyd

B.S.

, Chisari

F.V.

Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851–3854.

36.

Lim

S.G.

, Cheng

, Guindon

Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007; 133: 951–958.